High Note Wealth’s PTC Therapeutics PTCT Stock Holding History

High Note Wealth’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.69K	Buy	82 +11	+15%	+$794	﹤0.01%	497
2026 Q1	$4.84K	Buy	+71	New	+$5.03K	﹤0.01%	548

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

High Note Wealth's PTCT Position: Q2 2026 in Review

High Note Wealth increased its PTC Therapeutics (PTCT) stake by 15% in Q2 2026, buying an estimated $794 and bringing the position to 82 shares worth $6.69K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

High Note Wealth first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

High Note Wealth held 82 shares of PTC Therapeutics worth $6.69K as of Q2 2026.
High Note Wealth bought 11 PTC Therapeutics shares in Q2 2026, an estimated $794.
PTC Therapeutics made up ﹤0.01% of High Note Wealth's portfolio in Q2 2026, its #497 holding.
High Note Wealth first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on High Note Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.